Precision Biosciences

NASDAQ: DTIL
Engineering advanced therapies for genetic and oncological diseases through genome editing.

Sector

Life Sciences

Category

Therapeutics

Location

Durham, NC

Initial Investment

2015
Engineering advanced therapies for genetic and oncological diseases through genome editing.

Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics.